Online treatment for emotional disorders in adults with long COVID-19
Effectiveness and Acceptability of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in People With Long COVID-19.
This study is testing if an online treatment for emotional issues can help adults with long COVID-19 feel better compared to regular care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 90 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Instituto de Investigación Sanitaria Aragón Academic / other |
| Locations | 2 sites (Zaragoza, Zaragoza and 1 other locations) |
| Trial ID | NCT06928480 on ClinicalTrials.gov |
What this trial studies
This randomized controlled trial evaluates the effectiveness and acceptability of the Unified Protocol (UP) delivered in an online group format for treating emotional disorders in adults diagnosed with long COVID-19. The study will involve 90 participants, divided into a control group and an experimental group, who will receive either the UP or treatment as usual. The trial aims to assess changes in emotional disorders and cognitive complaints over a 12-month period, while also measuring chronic stress levels through cortisol analysis. Participants will be recruited from Hospital Royo Villanova in Zaragoza, Spain.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older, residing in Aragon, Spain, who have been diagnosed with long COVID-19 and exhibit symptoms of emotional disorders.
Not a fit: Patients with pre-existing emotional disorders prior to COVID-19 or those currently receiving psychological treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly improve emotional well-being and quality of life for patients suffering from long COVID-19.
How similar studies have performed: Other studies have shown success with transdiagnostic approaches for emotional disorders, suggesting potential for this intervention.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Residing in Autonomous Community of Aragon (Spain). * Being at least 18 years old. * Understanding of Spanish. * Being diagnosed with long COVID-19: documented SARS-CoV-2 infection and persistence of symptoms beyond 12 weeks after the acute infection. * Symptoms of depression (ODSIS≥7) and/or anxiety (OASIS≥8). * Meeting the criteria for an emotional disorder diagnosis. * Having access to Internet. * Signing the informed consent. Exclusion Criteria: * Pre-existing emotional symptoms prior to the acute SARS-CoV-2 infection. * Actually receiving psychological treatment. * Having a diagnosis of severe mental disorder (e.g., personality disorder, bipolar disorder, etc.). * Active suicidal ideation at the time of the assessment. * Individuals on psychotropic medication must maintain their dosage throughout the study, unless medically contraindicated.
Where this trial is running
Zaragoza, Zaragoza and 1 other locations
- Hospital Royo Villanova — Zaragoza, Zaragoza, Spain (Not_yet_recruiting)
- Hospital Royo Villanova — Zaragoza, Spain (Recruiting)
Study contacts
- Study coordinator: Jorge Osma Jorge Osma, PhD
- Email: osma@unizar.es
- Phone: +34 978645390
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.